Gyre Therapeutics (NASDAQ:GYRE) Shares Down 3.2% – Here’s Why

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) fell 3.2% during trading on Monday . The company traded as low as $10.41 and last traded at $10.44. 45,861 shares traded hands during trading, a decline of 53% from the average session volume of 97,472 shares. The stock had previously closed at $10.79.

Gyre Therapeutics Stock Performance

The business’s 50 day simple moving average is $12.49 and its 200 day simple moving average is $12.69.

Insiders Place Their Bets

In other Gyre Therapeutics news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total transaction of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at approximately $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 10,000 shares of company stock worth $118,680 in the last 90 days. Corporate insiders own 19.52% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds have recently modified their holdings of the company. Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after buying an additional 6,855 shares during the period. Geode Capital Management LLC raised its stake in shares of Gyre Therapeutics by 16.9% during the third quarter. Geode Capital Management LLC now owns 303,647 shares of the company’s stock valued at $3,808,000 after purchasing an additional 43,840 shares during the period. State Street Corp grew its position in shares of Gyre Therapeutics by 8.8% during the third quarter. State Street Corp now owns 104,490 shares of the company’s stock worth $1,310,000 after buying an additional 8,412 shares in the last quarter. FMR LLC acquired a new stake in shares of Gyre Therapeutics during the third quarter worth approximately $47,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of Gyre Therapeutics during the third quarter worth approximately $334,000. 23.99% of the stock is owned by institutional investors and hedge funds.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.